期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CHOP和R-CHOP方案治疗弥漫性大B细胞淋巴瘤的成本-效果分析 被引量：1

Cost-effectiveness Analysis of CHOP and R-CHOP Regimen for Native Diffuse Large B-cell Lymphoma
下载PDF
导出
摘要 目的:评价CHOP和利妥昔单抗联合CHOP(即R-CHOP)两种化疗治疗初治弥漫性大B细胞淋巴瘤的经济学效果。方法:46例患者随机分为2组,CHOP组16例,接受每3周为1个疗程的环磷酰胺+阿霉素+长春新碱+口服泼尼松的CHOP治疗方案;R-CHOP组30例,接受在每个疗程开始的第1天联合使用利妥西单抗的R-CHOP治疗方案,平均疗程均为4.5;评价2组的疗效及不良反应,并进行成本-效果分析。结果:CHOP和R-CHOP组总有效率分别为81.3%和90.0%,总成本分别为367.51和25825.96元;成本-效果比分别为4.52和286.96,两者间增量成本-效果比为2926.26;不良反应发生率两组比较相似(68.8%vs73.3%),差异无显著性(P=0.742)。结论:R-CHOP方案治疗CD20阳性的弥漫大B细胞型NHL与单纯CHOP方案相比总有效率略高,但CHOP方案成本-效果优于R-CHOP方案。 OBJECTIVE： To evaluate the cost - effectiveness outcome of R - CHOP （the combination of Rituximab and CHOP） and CHOP regimen in the therapy of native diffuse large B - cell lymphoma （DLBCL）. METHODS： A retrospective analysis was used to compare R - CHOP and CHOP regimen according to pharmacoeeonomic cost - effectiveness method. A total of 46 patients in SYSUCC were enrolled： 16 received CHOP regimen （CHOP group） and 30 received R- CHOP regimen （R - CHOP group）. RESULTS： The C/E ratio of CHOP and R - CHOP group were 4.52 and 286.96,respectively. And the incremental cost effectiveness ratio was 2 926.26. CONCLUSION ： The efficacy of CHOP regimen in the treatment of DLBCL was comparable to the R - CHOP regimen, but the cost - effectiveness of the former was superior of the two regimens.
作者 黄红兵 刘韬 陈倩超 林子超 何善超 潘莹 徐月红
机构地区 华南肿瘤学国家重点实验室 中山大学药学院
出处 《中国医院用药评价与分析》 2009年第3期204-206,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 大B细胞淋巴瘤 CHOP R-CHOP 药物经济学 成本-效果分析 Large B - cell lymphoma CHOP R- CHOP Pharmacoeconomic Cost - effective analysis
分类号 R956 [医药卫生—药学]
  • 相关文献

参考文献6

二级参考文献16

  • 1陈文 王龙兴.药物经济学研究.卫生经济学的理论与实践（第1版）[M].上海:上海交通大学出版社,1998.230-247.
  • 2胡善联.药物经济学与药品政策研究（第1版）[M].昆明:云南科技出版社,1999.61-62.
  • 3Coiffier B, Lepage E. Prognosis of aggressive lymphomas :a study of five prognostic models with patients included in the LNH-84 regimen [J]. Blood, 1989,74(2) :558-564.
  • 4Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 [J]. Blood, 1994,83(2) :435-445.
  • 5Coiffier B, Haioun C, Ketterer N, et al. Rituximab (antiCD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma., a multicenterphase Ⅱ study [J]. Blood, 1998,92(6) : 1927-1932.
  • 6The Non-Hodgkin's Lymphoma Pathologic Classification Project.National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage [J]. Cancer, 1982,49(10) : 2112-2135.
  • 7Tedder TF, Engel P. CD20:a regulator of cell-cycle progression of B lymphocytes [J]. Immunol Today, 1994,15(9):450-454.
  • 8Demidem A,(IDEC-C2B8)lymphoma cellCancer BiotherLam T, Alas S, et al. Chimeric anti-CD20 monoclonal antibody sensitizes a B cell line to cell killing by cytotoxic drugs [J].Radiopharm, 1997, 12(3) : 177-186.
  • 9Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma [J]. N Engl J Med, 2002,346(4) :235-242.
  • 10McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond totreatment program [J]. J Clin Oncol, 1998,162833.a four-dose(8):2825-2833.

共引文献95

同被引文献15

  • 1孙燕,石远凯.临床肿瘤内科手册[M].5版.北京:人民卫生出版社,2010:153-156.
  • 2ARMITAGE J O.My treatment approach to patients with diffuse large B-cell lymphoma[J].Mayo Clin Proc,2012,87(2):161-171.
  • 3SINHA R,NASTOUPIL L,FLOWERS C R.Treatment stra-tegies for patients with diffuse large B-cell lymphoma:past,present,and future[J].Blood Lymphat Cancer,2012,2012(2):87-98.
  • 4COIFFIER B,THIEBLEMONT C,VAN DEN NESTE E,et al.Long-term outcome of patients in the LNH-98.5 trial,the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients:a study by the Groupe d'Etudes des Lymphomes de I'Adulte[J].Blood,2010,116(12):2040-2045.
  • 5VOSE J M,LINK B K,GROSSBARD M L,et al.Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma[J].J Clin Oncol,2001,19(2):389-397.
  • 6COIFFIER B,LEPAGE E,BRIERE J,et al.CHOP chemo-therapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma[J].N Engl J Med,2002,346(4):235-242.
  • 7JOHNSTON K M,MARRA C A,CONNORS J M,et al.Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia,Canada[J].Value Health,2010,13(6):703-711.
  • 8BADIN F,HAYSLIP J.Rituximab in the treatment for B-cell non-hodgkin lymphoma,focus on outcomes and comparative effectiveness[J].Clinicoecon Outcomes Res,2010,2(1):37-45.
  • 9The Non-Hodgkin's Lymphoma Classification Project.Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients[J].Ann Oncol,1997,8(10):973-978.
  • 10A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma.The non-Hodgkin's lymphoma classification project[J].Blood,1997,89(11):3909-3918.

引证文献1

二级引证文献1

中国医院用药评价与分析
2009年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部